ipos0_l

Regeneron’s Eylea wins FDA approval for wet age-related macular degeneration

pharmafile | August 20, 2018 | News story | Sales and Marketing Bayer, Eylea, FDA, Regeneron, US, pharma 

Regeneron is celebrating the approval in the US of its vascular endothelial growth factor (VEGF) inhibitor Eylea (aflibercept) for the treatment of wet age-related macular degeneration (AMD).

The decision was based on second-year Phase 3 data from two trials, demonstrating the efficacy of Eylea in treating wet AMD with a 12-week dosing schedule.

Earlier the same week, the US regulator had voiced its dissatisfaction in the level of data supplied in support of the drug in a complete response letter, but had changed its mind by the Friday, with no reason given for the U-turn.

“We are pleased that the FDA has approved an updated label for EYLEA,” said Dr George D Yancopoulos, President and Chief Scientific Officer of Regeneron. “Providing information to retinal physicians about the visual outcomes with a modified 12-week dosing schedule will help physicians make the most informed choices in treating patients suffering from wet age-related macular degeneration.”

Advertisement

Last month, Eylea also secured approval in Europe, under Regeneron’s partner Bayer, who is handling commercialisation in the region. Overall, the drug is now approved for the treatment of wet AMD on four- and eight-week dosing intervals after three initial monthly doses.

Matt Fellows

Related Content

Evotec and Bayer announce new kidney disease study

Evotec and Bayer have announced the initiation of a phase 2 clinical study in kidney …

Rethinking oncology trial endpoints with generalised pairwise comparisons

For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …

Sharp invests $100m in US and EU manufacturing and packaging facilities

Sharp Services, a pharmaceutical packaging and sterile manufacturing specialist, has announced investments totalling $100m across …

The Gateway to Local Adoption Series

Latest content